Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Feb;18(2):136-45.
doi: 10.1097/JGP.0b013e3181c796eb.

Sertraline for the treatment of depression in Alzheimer disease

Paul B Rosenberg  1 , Lea T Drye, Barbara K Martin, Constantine Frangakis, Jacobo E Mintzer, Daniel Weintraub, Anton P Porsteinsson, Lon S Schneider, Peter V Rabins, Cynthia A Munro, Curtis L Meinert, Constantine G Lyketsos; DIADS-2 Research Group
Affiliations
Randomized Controlled Trial

Sertraline for the treatment of depression in Alzheimer disease

Paul B Rosenberg et al. Am J Geriatr Psychiatry. 2010 Feb.

Abstract

Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled "Depression in Alzheimer's Disease-2" to assess the efficacy and tolerability of sertraline for depression in AD.

Methods: One hundred thirty-one participants from five U.S. medical centers with mild-to-moderate AD (Mini-Mental State Examination scores 10-26) and depression of AD were randomized to double-blinded treatment with sertraline (N = 67) or placebo (N = 64), with a target dosage of 100 mg daily. Efficacy was assessed using logistic regressions and mixed effects models in an intention-to-treat analysis with imputation of missing data. Principal outcome measures were modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC), change in Cornell Scale for Depression in Dementia (CSDD) scores, and remission defined by both mADCS-CGIC score <or=2 and CSDD score <or=6.

Results: mADCS-CGIC ratings (odd ratio [OR = 1.01], 95% confidence interval [CI]: 0.52-1.97, p = 0.98), CSDD scores (median difference at 12 weeks 1.2, 95% CI: 1.65-4.05, p = 0.41), and remission at 12 weeks of follow-up (OR = 2.06, 95% CI: 0.84-5.04, p = 0.11) did not differ between sertraline (N = 67) and placebo (N = 64). Sertraline-treated patients experienced more adverse events, most notably gastrointestinal and respiratory, than placebo-treated patients.

Conclusion: Sertraline did not demonstrate efficacy for the treatment depression symptoms in patients with AD. In addition, its use was associated with an increased incidence of adverse events. Thus, selective serotonin reuptake inhibitors may be of limited value for treating depression in patients with AD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT chart of patient flow in DIADS-2
Figure 2
Figure 2
CSDD medians* at each visit by treatment group. Error bars represent the range between the first and third quartiles.
See this image and copyright information in PMC

References

    1. Jonsson L, Eriksdotter Jonhagen M, Kilander L, et al. Determinants of costs of care for patients with alzheimer's disease. Int J Geriatr Psychiatry. 2006;21:449–459. - PubMed
    1. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The cache county study. Int J Geriatr Psychiatry. 2007 - PMC - PubMed
    1. Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in alzheimer's disease clusters into three groups: The cache county study. Int J Geriatr Psychiatry. 2001;16:1043–1053. - PubMed
    1. Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125–128. - PubMed
    1. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of alzheimer disease: Rationale and background. Am J Geriatr Psychiatry. 2002;10:129–141. - PubMed

Publication types

LinkOut - more resources